Celebrating Lombardi
It has been quite a weekend!
Then, on Saturday evening we had our 35th Lombardi Gala, held at The Anthem. It was a wonderful event.
|
|
Georgetown Lombardi Young Scholars Gain Hands-On Science Experience
A team of eager third graders from Van Ness Elementary in southeast Washington, D.C., teamed up with volunteers from Georgetown Lombardi for hands-on experiences with robotics, programming, biology and engineering designed to encourage students to think about careers in science and medicine. Read more about this program.
|
|
New Study Finds Personalized mRNA Vaccine Given with Immunotherapy Reduces Recurrence in High-Risk Melanoma Patients
A new study conducted by an international team of researchers, including clinical investigators at Georgetown Lombardi and John Theurer Cancer Center, demonstrates that a personalized cancer mRNA vaccine combined with immunotherapy reduces recurrence and improves survival for people with advanced melanoma. Read more about this research.
|
|
The 2023 MedStar Health-Georgetown University Research & Education Symposium is Monday, May 8 |
|
The MedStar Health-Georgetown University Research & Education Symposium will be held in person on Monday, May 8. Those who have registered can join investigators, educators, executive leaders, associates and collaborative partners from across our academic health center in person at the Bethesda North Marriott Hotel & Conference Center to share research, hear keynote speaker Eliseo J. Pérez-Stable, MD, director of the National Institute on Minority Health and Health Disparities at NIH, and more. View full symposium information.
|
|
Nominate a Candidate for the 2024 Pew-Stewart Scholars Program for Cancer Research Award by Monday, May 8
|
|
NCI Offers Drug Development Workshop: “Specialized Topics in Preclinical Development of Small Molecule Cancer Drugs”
The Division of Cancer Treatment and Diagnosis at NCI is hosting a virtual workshop consisting of six webinar sessions examining specialized topics that are important for the preclinical development of small molecule cancer drugs. Learn how to mitigate the risk of selected candidates during their later stages of product development and increase their chances of entering clinical evaluation. Topics will be addressed by subject matter experts from government, academia and industry. The workshop is free and consists of 60- to 90-minute webinar sessions that start at 1:00 p.m. on Thursdays and Fridays from June 22 to July 28. View more information and register.
|
|
Dahlgren Memorial Library to Subsidize Wiley Open Access Article Publication Charges
|
|
Shared Resources Spotlight |
|
This weekly series showcases Georgetown University’s Shared Resources, which provide Georgetown Lombardi researchers with access to state-of-the-art equipment and technical expertise to support their work. |
|
Shared Resource Spotlight: Animal Models Shared Resource – Preclinical Imaging Research Laboratory
Animal models are powerful cancer research tools that are vital to translational research. The Animal Models Shared Resource – Preclinical Imaging Research Laboratory (AMSR-PIRL) provides Georgetown Lombardi investigators with access to diverse, state-of-the-art services and expertise to support accurate, sensitive longitudinal imaging of cancer animal models to monitor tumor initiation, progression, metabolism and response to therapy. The imaging services provided by the AMSR-PIRL in D.C. include high-resolution, in vivo and ex vivo small animal imaging and image analysis using the Bruker 7 tesla magnetic resonance imaging and spectroscopy console, a small animal VisualSonics Vevo 3100 ultrasound workstation to supplement the existing Vevo 3100 in New Jersey, a mouse GE Lunar PIXImus DEXA instrument, and bioluminescent and visible to near-infrared spectroscopic imaging workstations (IVIS Lumina III in DC, IVIS Lumina X5 in NJ). Users can be trained to independently operate the IVIS (DC/NJ), Vevo 3100 (NJ), and Faxitron X-ray (DC).
New services now available: Anatomical, metabolic and functional MRI using the Bruker 7T/30 Biospec MRI.
|
|
Tuesday, May 2
11:00 a.m. - 1:00 p.m.
Dajun Lu, PhD candidate in Tumor Biology, presents “The Molecular Mechanisms Underlying the Pathophysiological Role of Membrane-Bound Proteolysis in Human Skin.” Mentors: Michael D. Johnson, PhD, and Chen-Yong Lin, PhD. Join this event in W302, New Research Building, or via Zoom.
|
|
Tuesday, May 2
4:00 - 5:00 p.m.
Presented by Jay Horton, MD, Dr. Robert C. and Veronica Atkins Chair in Obesity and Diabetes, Scott Grundy’s Director Chair, professor of internal medicine and molecular genetics, director of the Center for Human Nutrition, UT Southwestern Medical Center. Join this talk in the New Research Building Auditorium or via Zoom.
|
|
Clinical Research Unit’s Open House
Wednesday, May 3
2:00 - 4:00 p.m.
Learn about our clinical research team, services provided, and many resources available to promote and advance research protocols. Light refreshments will be served. Sponsored by GHUCCTS. Held on the first floor of the Pasquerilla Healthcare Center (1 PHC). View more information.
|
|
Thursday, May 4
8:00 - 10:00 a.m.
Presented by Joseph S. Ross, professor of medicine (General Medicine) and public health (Health Policy and Management), Yale School of Medicine; associate physician, Center for Outcomes Research and Evaluation, Yale-New Haven Health System; and co-director, National Clinician Scholars Program, Yale. Join this Grand Rounds via Zoom.
|
|
Thursday, May 4
4:00 - 5:00 p.m.
Presented by Dhirendra Simanshu, PhD, principal scientist and team lead – RAS Structural Biology, NCI RAS Initiative, Frederick National Laboratory for Cancer Research. Join this talk in the New Research Building Auditorium or via Zoom.
|
|
IO/Heme Working Group Meeting
Thursday, May 4
5:00 - 6:00 p.m.
Leila Shobab, MD, assistant professor, medicine, Georgetown University, and clinical investigator, Endocrine Program at MedStar Georgetown University-MedStar Washington Hospital Center, presents “Sex-Differences in Thyroid Cancer Immune Response.” Join this meeting via Zoom.
|
|
Friday, May 5
9:00 - 10:00 a.m.
|
|
Digital Storytelling to Impact the Attitudes and Beliefs of Clinical Faculty Teaching about the Care of Transgender and Gender-Diverse People
Friday, May 5 or Wednesday, May 10
12:00 - 1:00 p.m.
|
|
Funding and Award Opportunities |
|
DUE TODAY (5/1): Request for Applications: Pediatric Sarcomas
The Samuel Waxman Cancer Research Foundation, Alan B. Slifka Foundation and Israel Cancer Research Fund are pleased to issue a joint request for applications for collaborative applications focused on fusion-positive pediatric sarcomas. Note: Projects must involve collaboration between two research groups — one in North America and one in Israel — with different but complementary expertise. Proposals must justify the partnership through synergistic scientific aims. One successful collaborative project will be awarded $150,000 per year for two years, or a total of $300,000, with each university-based research group receiving $75,000 per year ($150,000). Proposals will be prioritized for funding based on their potential to contribute to understanding, preventing and effectively treating pediatric sarcomas, with an emphasis on Ewing sarcoma. View full RFA information. Submit letter of intent by 5 p.m., May 1, to Wylie Tene at wtene@waxmancancer.org.
|
|
FINAL WEEK: Children’s Cancer Foundation 2023 Call for Proposals
The Children's Cancer Foundation, Inc. (CCF) invites individuals from Maryland, D.C. and Northern Virginia conducting research and/or programs relevant to pediatric cancer to submit proposals for grant award consideration. CCF will be awarding multiple one-year grants for research; one one-year grant for research by a young investigator (Giant Food NextGen Award); and several one-year grants for support of an existing or new program that serves the pediatric cancer community. Applications must be submitted via email or file transfer service to Rose Ann Verrilli: rverrilli@childrenscancerfoundation.org no later than May 7 at 11:59 p.m. ET. Review and download application materials and guidelines.
|
|
NEW Federal Grants Digest: Colleges & Universities Edition
A weekly curated digest of federal funding opportunities of interest to colleges and universities to support programming, research, infrastructure and other efforts, provided by Thorn Run Partners. View report (week of April 26, 2023).
|
|
Federal Lung Cancer Funding Opportunities
The Lung Cancer Research Program (LCRP), part of the Congressionally Directed Medical Research Programs, has released its fiscal year 2023 funding opportunities. The LCRP looks to support highly innovative, high-risk early ideas as well as more advanced translation research and early stage clinical trials. In addition, it supports researcher development with a career development-focused award mechanism. Pre-application (letter of intent) is required. Direct questions to help@eBRAP.org or 301-682-5507. View the funding opportunities and application instructions for:
-
Career Development Award, Pre-application due May 2, 5:00 p.m. ET
-
Concept Award, Pre-application due May 2, 5:00 p.m. ET
-
Idea Development Award: Pre-application due May 10, 5:00 p.m. ET
-
Translational Research Award: Pre-application due May 10, 5:00 p.m. ET
|
|
2023 V Foundation Call for Pediatric Cancer Research Grants
This call for applications is specifically for pediatric cancer research. The sole nominee for Georgetown Lombardi may apply in either the V Scholar or the Pediatric Translational program type. Review the RFA and nomination form for each program to decide which program best fits: Pediatric V Scholar RFA / Nomination; Pediatric Translational RFA / Nomination. Nominations are due May 17; applications are due May 27. Those interested should submit a letter of intent to Sharon Levy (sgl5@georgetown.edu) by Friday, May 12.
|
|
Research With Activities Related to Diversity (ReWARD)
The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories. View more information and application instructions. Application due date: Monday, June 5, at 5:00 p.m.
|
|
Phi Beta Psi Grant Proposal Invitation
The goal of the Phi Beta Psi Charity Trust is to advance cancer research nationwide to improve prevention, diagnosis and treatment by providing research grants to qualified investigators addressing original questions and hypotheses to be explored in basic and clinical studies in the field of cancer. Research applications must be focused on brain, breast, colorectal, endometrial, lung, ovarian, pancreatic, gastrointestinal tract or prostate cancer. Preference is given to young investigators with documented evidence of potential for conducting novel research of either basic or clinical aspects of cancer and cancer-related problems. Applications from established investigators exploring new and innovative areas of cancer research also will be considered. Post-doctoral fellows are not eligible. View full application information. Direct questions to Marcy Colley, marcycolleypbp@gmail.com. Applications for grants must be submitted to the office of the National Second Vice President by Thursday, June 15.
|
|
NEW Federal Rare Cancers Funding Opportunities
The Rare Cancers Research Program (RCRP), part of the Congressionally Directed Medical Research Programs, has released its fiscal year 2023 funding opportunities. The RCRP was initiated in 2020 to provide support for research of exceptional scientific merit in the area of rare cancers research. Rare cancers are defined as cancers affecting 6 or fewer persons per 100,000 per year in the United States. Applicants will be required to provide a justification statement explaining the relevance of the investigated cancer types/subtypes that fall under the RCRP’s definition of rare cancers. Pre-application (letter of intent) is required. Direct questions to help@eBRAP.org or 301-682-5507. View the funding opportunities and application instructions for:
-
Idea Development Award: Pre-application due June 26, 5:00 p.m. ET
-
Resource and Community Development Award: Pre-application due June 26, 5:00 p.m. ET
-
Concept Award, Pre-application due July 14, 5:00 p.m. ET
|
|
NEW Federal Pancreatic Cancer Funding Opportunities
-
Idea Development Award: Pre-application due July 10, 5:00 p.m. ET
-
Translational Research Partnership Award: Pre-application due July 10, 5:00 p.m. ET
|
|
PCOSA Funding Opportunity from the Lung Cancer Research Program
The Lung Cancer Research Program (LCRP), which is part of the Congressionally Directed Medical Research Programs, has recently released a new fiscal year 2023 funding opportunity, Patient-Centered Outcomes and Survivorship Award (PCOSA). This award supports high-risk, high-reward research studies that span the spectrum of behavioral health science, survivorship, health outcomes and comparative effectiveness research, including quality of life, symptom and side effect management, resilience, co-morbid conditions, and examining the physical, psychological, social, and economic effects of lung cancer among patients and their families. Research must address at least one area of emphasis in the disparities or health outcomes/survivorship categories. Clinical trials allowed. LOI due July 20; application due August 10. Read more about the award. View the application instructions.
|
|
Meetings in italics should be attended by all fellows.
|
|
9:00 AM | Breast Research Meeting | Podium A / Zoom (dial 646-558-8656; Meeting ID: 528212194)
11:00 AM | GU/Melanoma Research Meeting | Podium A / Zoom (dial 646-558-8656; Meeting ID: 796253566)
12:15 PM | TBA | Podium A / online
4:00 PM | GU Tumor Board (on 1st/3rd Mondays of the month) | Podium A / Zoom (dial 646-558-8656; Meeting ID: 869742463)
|
|
9:00 AM | Hematology Path Conference - Inpatient Heme fellows + Outpatient Heme + BMT fellow | Podium A / Microsoft Teams (CME code: 80737; phone: 202-796-7323)
12:15 PM | TBA | Podium A / online
4:00 PM | Liver Tumor Board | WebEx (dial 844-302-0362; Meeting number (access code): 711 507 430, password: Mse4mGSA2N5)
5:00 PM | Breast Tumor Board | Podium A / Zoom (dial 646-558-8656; Meeting ID: 93777073374; CME code: 80044)
|
|
8:00 AM | Thoracic Tumor Board – Thoracic Fellow | Podium A / Zoom (dial 646-558-8656; Meeting ID: 941 1630 5835)
12:15 PM | TBA | Podium A / online
|
|
9:00 AM | Cancer Research Data Meeting | Amir Bagheri | “The Role of C-terminally Phosphorylated p27 as cJun/STAT3 Transcriptional Co-activator in Regulating Cell Cycle Progression” | W302 New Research Building or Zoom
9:30 AM | Head and Neck Tumor Board - Thoracic Fellow attendance encouraged as clinic allows | Microsoft Teams
12:15 PM | TBA | Podium A / online
12:30 PM | GI Research Meeting | WebEx (dial 844-302-0362, Meeting Number (access code): 712527865, HOST PIN: 5514)
|
|
7:00 AM | CNS Tumor Board | Zoom (dial 646-558-8656; Meeting ID: 378 807 316)
12:00 PM | Oncology Grand Rounds Lecture Series | Speaker TBA | Zoom
12:00 PM | TBA
|
|
Connect with Georgetown Lombardi on Social Media |
|
If you would like to share news or updates from your department, please get in touch with Sarah Riehl. |
|
|
|
|
|
|
